# Getinge > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/getingeb). ## Overview Getinge AB is a global provider of products and solutions for healthcare and life sciences, focusing on intensive care, cardiovascular procedures, operating rooms, sterile reprocessing, and life sciences. The company employs approximately 12,000 people worldwide and operates in over 135 countries. In 2024, Getinge reported strong growth in sales and order intake, particularly in ventilators and consumables for ECLS and Sterile Transfer. The company is headquartered in Gothenburg, Sweden, and continues to expand its product portfolio through strategic acquisitions like Paragonix Technologies, Inc. ## Products & services • Intensive care solutions • Cardiovascular procedure products • Operating room equipment • Sterile reprocessing solutions • Life science products • ECLS consumables • Transplant care systems - **Intensive Care** (30%) — Includes ventilators and related equipment for critical care environments. - **Cardiovascular Procedures** (20%) — Products for cardiovascular surgeries and interventions. - **Operating Rooms** (15%) — Equipment and solutions for surgical environments. - **Sterile Reprocessing** (15%) — Solutions for sterilization and infection control. - **Life Sciences** (10%) — Products for research and development in life sciences. - **ECLS and Transplant Care** (10%) — Consumables and systems for extracorporeal life support and organ transplant. - Intensive care solutions - Cardiovascular procedure products - Operating room equipment - Sterile reprocessing solutions - Life science products - ECLS consumables - Transplant care systems ## Customers Getinge serves a diverse range of customers in the healthcare and life sciences sectors, including hospitals, surgical centers, and research institutions. The company's products are critical for intensive care units, operating rooms, and laboratories, making them essential for healthcare providers globally. Customers value Getinge's solutions for their reliability, innovation, and ability to enhance patient outcomes. The company's recent focus on expanding its transplant care offerings has attracted attention from specialized medical centers. - **Hospitals** (primary) — Purchase intensive care and cardiovascular products for critical care. - **Surgical Centers** (primary) — Acquire operating room equipment for surgical precision. - **Research Institutions** (secondary) — Utilize life science products for scientific studies. - **Specialized Medical Centers** (emerging) — Interested in ECLS and transplant care systems. - Hospitals purchase intensive care and cardiovascular products for critical patient care. - Surgical centers acquire operating room equipment to enhance surgical precision and safety. - Research institutions utilize life science products for advanced scientific studies. - Healthcare providers rely on sterile reprocessing solutions to maintain infection control. - Specialized medical centers are interested in ECLS and transplant care systems for organ transplants. ## Geography Getinge operates globally, with a strong presence in Europe, North America, and Asia. The company is headquartered in Gothenburg, Sweden, and its products are sold in more than 135 countries. This extensive geographic reach allows Getinge to tap into diverse markets and mitigate regional risks. The company's strategic acquisitions, such as Paragonix Technologies, enhance its product offerings and market penetration in key regions. - Headquartered in Gothenburg, Sweden, with a global operational footprint. - Products sold in over 135 countries, ensuring wide market reach. - Strong presence in Europe, North America, and Asia, driving sales growth. - Strategic acquisitions enhance market penetration in key regions. - Geographic diversity helps mitigate regional economic and political risks. ## Strategy Getinge's strategic priorities include enhancing productivity and cost efficiency through structural measures, focusing on high-growth areas like ECLS and transplant care, and phasing out less profitable segments such as surgical perfusion. The company aims to leverage its strong cash flow and earnings to drive profitability and sustain long-term growth. Strategic acquisitions, like that of Paragonix Technologies, are central to expanding its product portfolio and market presence. - **Enhancing productivity and cost efficiency** (medium-term) — To strengthen operating margins and profitability. - **Focusing on high-growth areas** (long-term) — To capture market opportunities in ECLS and transplant care. - **Phasing out surgical perfusion** (short-term) — To reallocate resources to more profitable segments. - Enhance productivity and cost efficiency through structural measures. - Focus on high-growth areas like ECLS and transplant care. - Phase out less profitable segments such as surgical perfusion. - Leverage strong cash flow and earnings for sustained growth. - Strategic acquisitions expand product portfolio and market presence. ## Risks Getinge faces several risks, including geopolitical uncertainties and potential trade barriers that could impact its global operations. The company's decision to phase out the surgical perfusion segment reflects the risk of limited market growth and unsatisfactory market share. Additionally, the healthcare industry is subject to regulatory changes that could affect product approvals and market access. Currency fluctuations and economic downturns in key markets also pose financial risks. - **Geopolitical uncertainties** [high] — Potential trade barriers could impact global operations. - **Limited market growth in surgical perfusion** [medium] — Market share is unsatisfactory, leading to strategic phase-out. - **Regulatory changes** [high] — Could affect product approvals and market access. - **Currency fluctuations** [medium] — Impact financial performance due to global operations. - Geopolitical uncertainties and trade barriers impacting global operations. - Limited market growth and unsatisfactory market share in surgical perfusion. - Regulatory changes affecting product approvals and market access. - Currency fluctuations impacting financial performance. - Economic downturns in key markets posing financial risks. ## Accounting Getinge's financial statements are influenced by critical accounting matters such as revenue recognition, which is affected by the timing of sales and delivery of products. The company experiences seasonal fluctuations in demand, particularly in the healthcare sector, which can impact quarterly revenue and cost comparability. Additionally, the valuation of acquired intangibles and goodwill requires significant judgment, especially following acquisitions like Paragonix Technologies. Currency translation adjustments also affect reported financial results due to Getinge's extensive international operations. - **Revenue recognition timing** — Significant - **Seasonal demand fluctuations** — Moderate - **Valuation of acquired intangibles** — Significant - **Currency translation adjustments** — Moderate - Revenue recognition timing affects sales and delivery reporting. - Seasonal demand fluctuations impact quarterly revenue comparability. - Valuation of acquired intangibles and goodwill requires judgment. - Currency translation adjustments affect financial results. - Acquisitions like Paragonix Technologies influence intangible asset valuation. --- *Last updated: 2026-08-11T04:04:52.910708+00:00*